Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA ODE II Directorship Open; Kweder Tapped As Office Of New Drugs Deputy

Executive Summary

FDA is looking to fill the Office of Drug Evaluation II director position following the appointment of Sandra Kweder, MD, to the Office of New Drugs as deputy director

You may also be interested in...



FDA Pediatric/Counterterrorism Office Will Announce Division Directors In Fall

FDA's Office of Counterterrorism and Pediatric Drug Development (OCTAP) is expected to announce directors for its separate counterterrorism and pediatric drug divisions in the fall

FDA Pediatric/Counterterrorism Office Will Announce Division Directors In Fall

FDA's Office of Counterterrorism and Pediatric Drug Development (OCTAP) is expected to announce directors for its separate counterterrorism and pediatric drug divisions in the fall

ODE II Director Is Pulmonary & Allergy Division Chief Meyer

Pulmonary & Allergy Drug Products Division Director Robert Meyer, MD, will become Office of Drug Evaluation II director effective June 16

Related Content

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel